Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs

 Interesting article for rheumatoid arthritis sufferers

Patients from pivotal 24-week phase 3 trial RA-BUILD who entered long-term extension study, RA-BEYOND, demonstrate baricitinib continues to inhibit radiographic progression of structural joint damage over one year INDIANAPOLIS, June 9, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that data from a pivotal long-term extension study, RA-BEYOND,…

Save

Comments are closed.